A detailed history of Willis Johnson & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Willis Johnson & Associates, Inc. holds 3,088 shares of ABBV stock, worth $542,191. This represents 0.05% of its overall portfolio holdings.

Number of Shares
3,088
Previous 3,188 3.14%
Holding current value
$542,191
Previous $546,000 11.54%
% of portfolio
0.05%
Previous 0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$163.84 - $199.33 $16,384 - $19,933
-100 Reduced 3.14%
3,088 $609,000
Q2 2024

Aug 01, 2024

SELL
$154.79 - $180.76 $12,228 - $14,280
-79 Reduced 2.42%
3,188 $546,000
Q1 2024

Apr 19, 2024

SELL
$159.82 - $182.1 $1,758 - $2,003
-11 Reduced 0.34%
3,267 $594,000
Q4 2023

Jan 12, 2024

BUY
$137.6 - $154.97 $7,017 - $7,903
51 Added 1.58%
3,278 $507,000
Q3 2023

Oct 25, 2023

BUY
$133.59 - $154.65 $110,211 - $127,586
825 Added 34.35%
3,227 $481,000
Q2 2023

Jul 17, 2023

SELL
$132.51 - $164.9 $4,637 - $5,771
-35 Reduced 1.44%
2,402 $323,000
Q1 2023

Apr 06, 2023

BUY
$144.61 - $166.54 $18,365 - $21,150
127 Added 5.5%
2,437 $388,000
Q4 2022

Jan 20, 2023

SELL
$138.31 - $165.87 $50,206 - $60,210
-363 Reduced 13.58%
2,310 $0
Q3 2022

Oct 12, 2022

SELL
$134.21 - $153.93 $46,034 - $52,797
-343 Reduced 11.37%
2,673 $359,000
Q2 2022

Jul 18, 2022

SELL
$137.62 - $174.96 $14,862 - $18,895
-108 Reduced 3.46%
3,016 $462,000
Q1 2022

May 10, 2022

BUY
$131.98 - $163.75 $104,000 - $129,035
788 Added 33.73%
3,124 $506,000
Q4 2021

Jan 21, 2022

BUY
$107.43 - $135.93 $30,187 - $38,196
281 Added 13.67%
2,336 $316,000
Q3 2021

Oct 15, 2021

SELL
$106.4 - $120.78 $18,407 - $20,894
-173 Reduced 7.76%
2,055 $222,000
Q2 2021

Jul 16, 2021

BUY
$105.21 - $117.21 $5,155 - $5,743
49 Added 2.25%
2,228 $251,000
Q1 2021

Apr 29, 2021

BUY
$102.3 - $112.62 $222,911 - $245,398
2,179 New
2,179 $236,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Willis Johnson & Associates, Inc. Portfolio

Follow Willis Johnson & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Willis Johnson & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Willis Johnson & Associates, Inc. with notifications on news.